HOME >> MEDICINE >> NEWS
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95

at high risk of venous thrombosis (formation of a blood clot in a vein) which may result in pulmonary embolism leading to death. A common approach to prevention of venous thromboembolism is the use of anticoagulant prophylaxis e.g. injectable low molecular weight heparin or oral warfarin. Warfarin requires careful and regular coagulation monitoring i.e. taking blood samples. Warfarin has limitations because of a slow onset of effect over several days. Also, bleeding complications and drug interactions are common. There is, therefore, a need for an effective and well-tolerated oral alternative to warfarin. The data from the METHRO II study indicate that H 376/95 shows considerable promise as a replacement for low molecular weight heparin and warfarin in the prophylaxis of venous thromboembolism in orthopaedic surgery."

The METHRO II study was a double-blind, dose-finding study and a comparator agent was used. The primary purpose of the study was to determine the dose-response relationship with regard to efficacy for the oral direct thrombin inhibitor, H 376/95, preceded by subcutaneous administration of melagatran. The METHRO II study was also designed to compare the efficacy of the H 376/95 regimen with conventional prophylaxis using the injectable low molecular weight heparin agent, dalteparin.

Patients were randomised to one of four melagatran/H 376/95 regimens or dalteparin for 8-11 days. The regimens were: 1mg, 1.5mg, 2.25mg or 3mg melagatran subcutaneously twice daily followed by 8mg, 12mg, 18mg or 24mg oral H 376/95 twice daily respectively or dalteparin 5000 IU once daily subcutaneously. A diagnostic procedure, phlebography, was carried out on the final day of treatment. Patient follow-up was 4-6 weeks post-operatively. Two-thirds of the patients underwent hip replacement and one-third knee replacement surgery. The age range was 18-85 years.

There was a clear relationship between the dose regimen of H 376/95 and the occurrence of
'"/>

Contact: Jonathan Wilson/Rebecca Hunt
jonathan.wilson@ketchumcomms.co.uk
44-207-465-7698
Ketchum
4-May-2000


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... “surprising habits” that may sometimes lead to, or worsen, varicose veins in some ... Center notes that, while avoiding certain not-so-good practices, like excessive sitting or standing, ...
(Date:7/18/2017)... Massachusetts (PRWEB) , ... July 18, 2017 , ... ... medical device compliance and commercialization, has just announced two more sessions of its ... usability engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the ...
(Date:7/18/2017)... ... 2017 , ... An inventor from Anacortes, Wash., knows the difficulties and indignity ... hot flashes, and I suffer from anxiety and vertigo on top of that," she ... and about." INSTA-FAN meets that need. , This device enables a woman in menopause ...
(Date:7/18/2017)... ... July 18, 2017 , ... FCPX LUT Berlin for ... any media. FCPX LUT Berlin includes 60 different color-grade presets, giving FCPX users numerous ... vignettes and blurs to emphasize each subject, plus much more. FCPX LUT Berlin is ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... for parents and camp staff to ensure children are protected from Lyme and ... this year, children are at an increased risk not only for the tick-borne ...
Breaking Medicine News(10 mins):
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)... 30, 2017  AVACEN Medical (AVACEN) announced the publication of new ... the use of its AVACEN Treatment Method to significantly ... ... AVACEN Medical ... widespread pain. It affects approximately 200 to 400 million people worldwide according ...
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. ... pharmaceutical company specializing in the development of cannabinoid-based drugs, ... Stock Market Opening Bell in New York, ... honor of its initial public offering (IPO) of American ... in March 2017. Dr. Elran Haber, Ph.D., ...
Breaking Medicine Technology:
Cached News: